PMID- 27508949 OWN - NLM STAT- MEDLINE DCOM- 20170531 LR - 20170531 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 124 IP - 11 DP - 2016 Nov TI - The positive predictive value of "suspicious for high-grade urothelial carcinoma" in urinary tract cytology specimens: A single-institution study of 665 cases. PG - 811-819 LID - 10.1002/cncy.21764 [doi] AB - BACKGROUND: "The Paris System" proposes a 7-tier classification system for urine cytology. Establishing the risk of malignancy (ROM) associated with these diagnostic categories is essential to determine the appropriate management of patients. The objective of this study was to determine the ROM associated with the "positive" and "suspicious" categories. METHODS: The authors searched their electronic records for urine cytology specimens that had been diagnosed as "positive" or "suspicious" for high-grade urothelial carcinoma within an 11-year time frame. Then, the ROM was determined for these specimens within a 6-month follow-up interval. The cytologic diagnoses were correlated with surgical biopsy results, follow-up cytology results, and/or fluorescence in situ hybridization (FISH) results. RESULTS: In total, 662 specimens (487 "positive" and 175 "suspicious"), corresponding to 387 patients (295 men and 92 women), were included. The majority of specimens were collected by bladder washing (568 of 662 specimens; 85.4%) and for the indication of surveillance (601 of 662 specimens; 82%). On follow-up, bladder washing specimens were positive more often positive than voided urine specimens (466 of 570 [81.8%] vs 60 of 92 [65.2%]; P = .0005), and surveillance specimens were more often positive than specimens collected for other indications (82% vs 54.1%). The overall positive predictive value was higher for positive specimens than for suspicious specimens (365 of 461 [79.2%] vs 83 of 150 [55.3%]; P < .0001). CONCLUSIONS: Diagnoses of suspicious for high-grade urothelial carcinoma, as used at the authors' institution, have an ROM that is high but is lower than that for the "positive" category. Therefore, the authors suggest keeping the 2 categories separate, although management should be aggressive in both groups. Cancer Cytopathol 2016;124:811-9. (c) 2016 American Cancer Society. CI - (c) 2016 American Cancer Society. FAU - Joudi, Anthony M AU - Joudi AM AD - Department of Pathology, Loyola University Medical Center, Maywood, Illinois. FAU - Pambuccian, Stefan E AU - Pambuccian SE AD - Department of Pathology, Loyola University Medical Center, Maywood, Illinois. FAU - Wojcik, Eva M AU - Wojcik EM AD - Department of Pathology, Loyola University Medical Center, Maywood, Illinois. FAU - Barkan, Guliz A AU - Barkan GA AD - Department of Pathology, Loyola University Medical Center, Maywood, Illinois. LA - eng PT - Journal Article DEP - 20160810 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 SB - IM MH - Carcinoma/*diagnosis/pathology MH - Cytodiagnosis/methods/standards MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence/methods/standards MH - Male MH - Neoplasm Grading MH - Predictive Value of Tests MH - Retrospective Studies MH - Sensitivity and Specificity MH - Urethral Neoplasms/*diagnosis/pathology OTO - NOTNLM OT - cytopathology OT - fluorescence in situ hybridization (FISH) OT - the Paris System OT - urinary cytology OT - urothelial carcinoma EDAT- 2016/08/11 06:00 MHDA- 2017/06/01 06:00 CRDT- 2016/08/11 06:00 PHST- 2016/04/29 00:00 [received] PHST- 2016/05/27 00:00 [revised] PHST- 2016/06/02 00:00 [accepted] PHST- 2016/08/11 06:00 [pubmed] PHST- 2017/06/01 06:00 [medline] PHST- 2016/08/11 06:00 [entrez] AID - 10.1002/cncy.21764 [doi] PST - ppublish SO - Cancer Cytopathol. 2016 Nov;124(11):811-819. doi: 10.1002/cncy.21764. Epub 2016 Aug 10.